达帕格利弗洛辛在复发性炎中的安全性和有效性:试点研究
Virendra Singh1,2, Arka De3, Rishav Aggrawal3
1Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. virendrasingh100@hotmail.com.
Digestive diseases and sciences
|October 9, 2024
概括
达帕格利弗洛辛改善了肝硬化患者的控制和自然,但增加了急性损伤和感染的风险,但没有改善存活率.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 肝病学 肝病学是一种肝病学.
- 心脏病学 心脏病学
背景情况:
- 肝硬化激活了氨酸- ангиотензин- алдостерон系统,导致和水的保留,导致.
- 达帕格利弗洛辛是一种与葡萄糖相关的运输体-2 抑制剂,在心力衰竭患者中促进自然尿.
- 达帕格利弗洛辛的潜在尿作用可能会减轻肝硬化患者的.
研究的目的:
- 评估达帕格利弗洛辛在肝硬化和复发性瘤患者的安全性和有效性.
- 评估达帕格利弗洛辛对风控制和自然化病的影响.
- 调查达帕格利弗洛辛对疾病严重程度得分,存活率和不良事件的影响.
主要方法:
- 试点研究涉及40名肝硬化和复发性瘤患者.
- 随机,双盲,安慰剂对照试验,使用达帕格利弗洛辛 (10 mg/天) 或安慰剂.
- 主要结局:在6个月后控制风. 二级结局:尿液输出,尿中的,CTP/MELD得分,生存率,AKI和感染.
主要成果:
- 与安慰剂相比,达帕格利弗洛辛显著改善了炎控制 (p=0.04) 和增加了尿路分泌 (p<0.001).
- 两组之间没有观察到尿量,CTP/MELD得分或存活率的显著差异.
- 达帕格利弗洛辛与急性损伤 (AKI) 和感染的发生率显著增加有关 (p=0.04).
结论:
- 达帕格利弗洛辛在控制炎和促进肝硬化患者的自然养方面表现出有效性.
- 治疗没有改善肝病严重性得分或患者存活率.
- 由于AKI和感染的风险增加,需要仔细考虑在这个人群中使用达帕格利弗洛辛.
更多相关视频
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
173
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
173
Acute Pancreatitis II: Clinical Manifestations and Management
94
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
94
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
2
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
2
Ultrasound II: Endoscopic Ultrasound and FibroScan
82
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
82
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
163
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
163


